Offers Claimed: 169
Downloaded Today: 98
Yes100% of Medicare Part D and Medicare Advantage plans cover this drug.
It depends. Which coverage stage are you in? Click on a tab below…
$5 – $22
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your phenobarbital prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Applies to phenobarbital: oral elixir, oral tablets, parenteral injection
Side effects include:
Residual sedation, drowsiness, lethargy, vertigo, nausea, vomiting, headache.For Healthcare Professionals
Applies to phenobarbital: compounding powder, injectable solution, oral capsule, oral elixir, oral tabletGeneral
The most commonly reported side effect was somnolence.Nervous system
Common (1% to 10%): Somnolence
Postmarketing reports: Sedation, residual sedation/"hangover" effect, drowsiness, lethargy, vertigo, localized/diffuse neuralgic pain, headache, hyperactivity, hypotension, hyperkinesia, ataxia, central nervous system (CNS) depression, dizziness, impairment of fine motor skills, Grand mal convulsion, prolonged coma, depressed/absent reflexes, nystagmus
Drowsiness/sedation tended to decrease with continued use.
Localized or diffuse neuralgic pain occurred, especially in psychoneurotic patients with insomnia. This pain was most frequently located in the neck, shoulders, and upper limbs and appeared in paroxysms that were most intense early in the morning. In some patients, the pain continued for days after discontinuation of this drug.
Hyperactivity occurred in pediatric and geriatric patients.Psychiatric
Postmarketing reports: Accentuated emotional disturbances/phobias, aggression, excitement/hyperexcitability, restlessness, delirium, irritability, agitation, confusion, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia/sleep disturbance, anxiety, abnormality in thinking, paradoxical reaction (unusual excitement), mental depression/depression, cognitive impairment, behavioral disturbances in children, abnormal behavior, mood altered, subtle mood changes, menstrually related mood disorder, suicidal ideation, memory/concentration/judgment impairment, withdrawal syndrome, tolerance, dependence, psychic/physical dependence, mental confusion/confusion, disorientation
Some patients have experienced paradoxical excitement, restlessness, or delirium in the presence of pain.
Paradoxical reactions, hallucinations, restlessness, hyperexcitability, and confusion have occurred in geriatric and pediatric patients. Pediatric patients were more likely to experience aggression or irritability.Immunologic
Postmarketing reports: Antiepileptic hypersensitivity syndrome (e.g., fever, rash, lymphadenopathy, lymphocytosis, eosinophilia, hematological abnormalities, hepatic and other organ involvement [renal, pulmonary])
Antiepileptic hypersensitivity syndrome typically occurred 1 to 8 weeks after first exposure or within 1 day of rechallenge. This syndrome may have cross reactivity with other antiepileptic agents.Dermatologic
Skin eruptions may be associated with fever, delirium, and marked changes in the liver and other organs.
Postmarketing reports: Erythematous dermatitis, exfoliative dermatitis (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), skin eruptions, maculopapular/morbilliform/scarlatiniform rashes, dermatitis, erythema multiforme, drug eruption, evidence of connective tissue changes, skin blisters/bullae, photosensitivity, erythroderma, urticariaMusculoskeletal
Postmarketing reports: Localized/diffuse myalgic or arthritic pain, osteomalacia, rickets, decreased bone mineral density, increased risk of fracture, Dupuytren's contracture, bone metabolism disorder, frozen shoulder, Ledderhose's syndrome, general joint pain, osteopenia, osteoporosis, fractures
Localized or diffuse myalgic or arthritic pain occurred, especially in psychoneurotic patients with insomnia. This pain was most frequently located in the neck, shoulders, and upper limbs and appeared in paroxysms that were most intense early in the morning. In some patients, pain continued for days after discontinuation of therapy.
Decreased bone mineral density, Dupuytren's contracture, osteopenia, osteoporosis, and fractures occurred in patients receiving long-term therapy; however, the exact mechanism of action in bones was not identified.Other
Postmarketing reports: Inebriation (drunk-like effect), fever, neonatal sedation, neonatal drug dependence/withdrawal, neonatal symptoms resembling vitamin K deficiency, neonatal bleeding due to vitamin K deficiency, congenital anomaly, cleft lip and palate, lowered body temperatureHematologic
Postmarketing reports: Megaloblastic anemia, macrocytic anemia, aplastic anemia, agranulocytosis, thrombocytopenia, hypoprothrombinemia, methemoglobinemia, purpura, lymphocytosis
Megaloblastic anemia occurred after chronic use of this drug, and may be due to folate deficiency.
Methemoglobinemia has occurred in infants nursed by mothers receiving this drug.Cardiovascular
Postmarketing reports: Circulatory collapse, peripheral vascular collapse, weak heartbeat, circulatory failure, bradycardia, hypotension, profound shock, vasodilationRespiratory
Postmarketing reports: Respiratory depression, severe/significant respiratory depression, apnea, hypoventilation, bronchospasm, laryngospasm
Bronchospasm and laryngospasm were reported, especially in patients given the IV formulation.Hepatic
Postmarketing reports: Abnormal hepatic function, hepatitis, liver damage, cholestasis, toxic hepatitis, jaundiceMetabolic
Postmarketing reports: Hypocalcemia, folate deficiency, abnormal vitamin D metabolism, increased vitamin D requirements (possibly resulting from abnormal vitamin D metabolism), vitamin K deficiency, hypophosphatemiaGastrointestinal
Postmarketing reports: Nausea, vomiting, constipation, diarrheaHypersensitivity
Hypersensitivity reactions generally consisted of acquired hypersensitivity. Patients with a higher risk of developing reactions were more likely to have asthma, urticaria, and angioedema.
Postmarketing reports: Localized swelling (e.g. eyelids, cheeks, lips), hypersensitivity reactions (e.g., angioedema, skin rashes, exfoliative dermatitis), angioedemaLocal
Postmarketing reports: Injection site reactions, local necrosis after extravasation (IV/subcutaneous injection)Renal
Postmarketing reports: Renal failureOncologic
Postmarketing reports: FibromasEndocrine
Postmarketing reports: Reduced serum concentrations of thyroid hormonesGenitourinary
Postmarketing reports: Peyronie's disease
July 8, 2021
March 23, 2021
March 19, 2021
February 15, 2021
September 25, 2020
July 13, 2020